Clinical trials: TACE
Hepatocellular Carcinoma
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC.
- Trial name
- NCT03066557
- Testing
- TACE and Apatinib, TACE
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HCV, HCC
the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths in the world.
- Trial name
- ZEPATIER (NCT03110055)
- Testing
- Grazoprevir/Elbasvir, Medical records, Transarterial Chemoembolization
- Volunteers
- 20 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
BCLC Stage C Hepatocellular Carcinoma
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage.
- Trial name
- NCT04992143
- Testing
- TACE, Tilelizumab, Sorafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hepatocellular Carcinoma
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular…
- Trial name
- NCT05250843
- Testing
- TACE/HAIC, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Child-Pugh Class A, Child-Pugh Class B
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
- Trial name
- NCT02507765
- Testing
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hepatocellular Carcinoma
"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance…
- Trial name
- NCT04317248
- Testing
- Cyclophosphamide, Multiple Signals loaded Dendritic Cells Vaccine
- Where
- 4 sites in China
- Volunteers
- 600 people
- Sponsor
- Yuehua Huang
Hepatocellular Carcinoma Non-resectable
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large…
- Trial name
- NCT04967482
- Testing
- Drug-eluting bead transarterial chemoembolization (DEB-TACE), Conventional transarterial chemoembolization (cTACE)
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
- Trial name
- TACE (NCT00539253)
- Testing
- gadobenate dimeglumine (MultiHance)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma (HCC)
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic…
- Trial name
- TACE HCC (NCT06990620)
- Testing
- TACE+AK112
- Volunteers
- 56 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer.
- Trial name
- TACE (NCT03895359)
- Testing
- Stereotactic Body Radiation, Transarterial Chemoembolization
- Where
- Canada
- Volunteers
- 128 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Carcinoma Non-resectable
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599790
- Testing
- TACE combined with lenvatinib and sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Gastric Cancer
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective, single-center, single-arm, phase 2 trial to evaluate the feasibility and safety of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and…
- Trial name
- NCT05346874
- Testing
- Oxaliplatin, Teysuno, Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
This clinical trial is a prospective, randomized, controlled and multicenter study.And the trial is going to better control intrahepatic tumors for hepatocellular carcinoma(HCC) patients who meet the inclusion criterion.The…
- Trial name
- TACE-EBRT (NCT03116984)
- Testing
- Transcatheter arterial chemoembolization, External- beam radiotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)
Most HCC patients are diagnosed at advanced stages in Korea, transcatheter arterial chemoembolization is considered a key modality for palliative treatment in these HCC patients.
- Trial name
- NCT00919009
- Testing
- TACE (Transcatheter Arterial Chemoembolization )
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Advanced Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.
- Trial name
- TACE (NCT02150317)
- Testing
- TACE+Sorafenib, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
China Liver Cancer Clinical Registry Cohort Database (HEAL)
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to…
- Trial name
- NCT06777485
- Testing
- Procedure/Surgery treatment, Anti-Tumor Drugs
- Where
- 38 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of…
- Trial name
- NCT00522405
- Testing
- TACE
- Where
- India
- Sponsor
- All India Institute of Medical Sciences
Advanced Adult Primary Liver Cancer
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
- Trial name
- NCT02557503
- Testing
- Oxaliplatin and fluorouracil
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu